bioMérieux ConnectionAn educational resource brought to you by bioMérieux, Inc.
An educational resource brought to you by bioMérieux, Inc.
As major progress was made in reducing the impact of other diseases, hepatitis became what the World Health Organization (WHO) refers to as a long-neglected epidemic, causing devastating and complex health problems. No longer overshadowed, hepatitis has moved into the spotlight as one of the world’s leading causes of death.
As cases of COVID-19 are on the rise again in several places in the U.S., the need for effective treatment remains. Many potential COVID-19 treatments that could have an impact on our ability to fight the virus are currently being developed or tested in clinical trials.
In the United States, Group B Streptococcus (GBS) bacteria are a leading cause of meningitis and sepsis in a newborn’s first three months of life. The bacteria may be passed from pregnant women to their babies during delivery, because about one in every four pregnant women carry GBS bacteria in their body.
The farthest-along candidates are a viral vector vaccine being tested by the University of Oxford and AstraZeneca, a repurposed vaccine, originally developed in the early 1900s for protection against tuberculosis, and a whole-virus vaccine being tested by the state-owned Chinese company Sinopharm.
At this year’s World Anti-Microbial Resistance Congress, Dr. Tristan Timbrook delivered a...
WASH, which stands for water, sanitation, and hygiene, are basic...